This is particularly important given the growing emphasis on early CKD detection and the availability of new drugs—such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists—which have strong cardio- and renoprotective effects and are now included in the updated KDIGO guidelines [41]. This evidence concerns the gene NR3C2 and chronic kidney disease.